Last updated: June 3, 2026
MULPLETA is a luspatercept-aamt product supplied through a defined manufacturing and labeling chain. The key “supplier” entities for MULPLETA are the companies involved in (i) drug substance and (ii) drug product manufacture, plus (iii) packaging and (iv) label/distribution.
What company supplies MULPLETA (luspatercept-aamt) in the US?
The commercial “supplier” for MULPLETA is Bristol Myers Squibb (BMS), which markets and distributes the product in the US under the brand MULPLETA (luspatercept-aamt).
Who is listed as manufacturer for MULPLETA on the FDA label?
The FDA product label for MULPLETA identifies the manufacturer responsibilities for the drug product and related operations (drug product manufacturing site(s) and packaging/labeling). Those entries are the source-of-record for “who supplies” for regulatory and procurement purposes because they map to CGMP manufacturing sites used for released lots.
Which companies manufacture luspatercept-aamt (drug substance) for MULPLETA?
For procurement due diligence and supply-chain risk, drug-substance manufacturers are typically identified in FDA Chemistry, Manufacturing, and Controls (CMC) sections and in the label’s manufacturing disclosures where applicable. For MULPLETA, the drug substance is produced by the company/companies contracted for luspatercept-aamt production under BMS oversight.
How to separate drug substance vs drug product suppliers for MULPLETA?
- Drug substance suppliers: produce luspatercept-aamt active ingredient (API) under CGMP.
- Drug product suppliers: formulate, fill, and finish the injectable (the syringe/ vial presentation) under CGMP.
- Packaging/labeling suppliers: handle final carton/bottle/syringe packaging and label application for commercial distribution.
What packaging and labeling suppliers are used for MULPLETA?
Packaging and labeling are part of the release chain for commercial lots. For MULPLETA, the label’s manufacturing section and distribution statements identify the firms that perform packaging/labeling operations tied to the approved presentation.
Which MULPLETA presentations affect the supplier network? (vials vs syringes)
MULPLETA is supplied as an injectable product; the exact presentation (container closure system) can change the fill-finish and packaging workflow. Supplier identification can therefore differ between:
- different container types (vial vs prefilled syringe), and
- different strengths (if applicable), and
- different countries/regions where commercial lots are released.
What supplier changes occur by strength or region?
Supplier-of-record can change based on:
- which manufacturing site is allocated to a given strength during the release plan,
- whether packaging/labeling is performed at the drug product site or at a regional packager, and
- whether the country-specific label uses local imprinting/labeling.
How strong is MULPLETA’s manufacturing and supply-chain risk profile by supplier concentration?
For high-value injectables with biologics-like supply economics, risk concentrates where there are single-site constraints:
- one or limited fill-finish sites,
- one API upstream site,
- high sensitivity to release testing throughput.
BMS’s supplier setup for MULPLETA is structured to maintain routine commercial continuity, but procurement risk generally increases during:
- capacity bottlenecks,
- OOS investigations,
- validation refresh cycles after tech transfer.
Key supplier map for MULPLETA (what matters for vendor qualification)
Procurement and quality teams typically qualify suppliers across these checkpoints:
| Supplier layer |
What it means for “supplier” |
What to verify for MULPLETA lots |
| Marketing/distribution principal |
Who sells and distributes the US product |
BMS as the commercial principal for MULPLETA |
| Drug product manufacturer |
Who fills and finishes the injectable |
Site listed for drug product manufacture on FDA label/CMC disclosures |
| Drug substance manufacturer |
Who makes luspatercept-aamt API |
API manufacturing site named in CMC and regulatory submissions |
| Packaging/labeling operations |
Who performs final packaging and label application |
Packaging/labeling operations listed in the approved labeling manufacturing section |
| Release testing and QA |
Who performs batch release testing under CGMP |
QA release controls referenced in regulatory submissions and site responsibilities |
What generic or biosimilar threats change MULPLETA supplier dynamics?
No generic pathway replaces a marketed biologic-like product directly in the way small molecules do; however, competitive entry risk can affect:
- volume forecasting,
- internal manufacturing rebalancing,
- tech transfer activities.
For MULPLETA, supplier pressure comes mainly from:
- capacity planning as demand forecasts change,
- contract renegotiations with fill-finish or packaging partners,
- potential tech transfers tied to supply assurance.
Which supplier entities are most relevant for procurement, litigation, and regulatory filings?
For business use cases:
- Procurement: use label-listed manufacturing sites and BMS’s distribution chain for vendor onboarding.
- Litigation: manufacturing contracts and lot-level evidence often matter, but the regulatory record points to specific CGMP sites.
- Regulatory: site changes require CMC reporting and comparability work; label and CMC tie to “who supplies” for regulatory credibility.
Key Takeaways
- MULPLETA is marketed and distributed by Bristol Myers Squibb (BMS) in the US.
- The “supplier” universe for MULPLETA is best defined by the CGMP drug product manufacturer, drug substance manufacturer, and packaging/labeling operations as reflected in the approved FDA label and regulatory CMC record.
- Supplier concentration risk is driven by API upstream and fill-finish site availability and release-test capacity.
FAQs
- Who is the marketing authorization holder for MULPLETA in the US?
- Which CGMP manufacturing sites are named for MULPLETA drug product and packaging on the US label?
- Does MULPLETA use different fill-finish suppliers by strength or presentation?
- How do supply-chain disruptions at API or fill-finish sites affect MULPLETA availability?
- What manufacturing disclosures govern “supplier” attribution in FDA inspections for MULPLETA lots?
References (APA)
- Bristol Myers Squibb. MULPLETA (luspatercept-aamt) prescribing information, US FDA label. FDA.
